Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Boston Pharmaceuticals Inc.

Latest From Boston Pharmaceuticals Inc.

Who Will Emerge As Best In Class Of The FGF21 Analogs In NASH?

Akero hopes to begin Phase III study of efruxifermin this year, with 89bio working to enter Phase III with pegozafermin in 2024. But just behind them, Boston Pharmaceuticals thinks it has a convenience and immunogenicity edge.

Business Strategies Clinical Trials

89bio’s FGF21 Analog May Offer Fibrosis Benefit In Cirrhotic NASH Patients

At AASLD, 89bio presented subgroup analysis from its successful Phase IIb NASH study indicating that the drug may meaningfully reduce fibrosis even in the sickest patients, those with cirrhosis.

Clinical Trials Business Strategies

Pieris Looks For Way Out After AstraZeneca Exits Respiratory Collaboration

The US biotech is hoping to either partner off its wholly owned pipeline or become a target for an acquisition or merger after AstraZeneca’s asthma exit left it with dwindling cash, and a need to cut costs.

Companies Business Strategies

Pieris Ponders Future As AstraZeneca Exits Asthma Pact

With a Phase II gastric cancer asset discontinued for financial reasons last year, the pipeline at Pieris is looking very bare now that AstraZeneca has discontinued a mid-stage trial of its asthma candidate elarekibep.

Respiratory Clinical Trials
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals